Skip to main content
. 2017 Jul 1;8(48):83637–83649. doi: 10.18632/oncotarget.18906

Figure 4. Ranking of treatments in terms of progression-free survival benefit (blue line) and high-grade adverse events (red line).

Figure 4

Ranking indicates the probability to be the best treatment, the second best, the third best, and so on, among the 9 immune checkpoint inhibitor-related treatments. CHE = chemotherapy. IPI = ipilimumab. TRE = tremelimumab. NIV = nivolumab. PEM = pembrolizumab. IPI_CHE = ipilimumab plus chemotherapy. IPI_NIV = ipilimumab followed by nivolumab. IPI_GP100 = ipilimumab plus glycoprotein 100. IPI_SAR = ipilimumab plus sargramostim.